Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
在 III 期 PAOLA-1/ENGOT-ov25 试验中，根据临床风险，对新诊断的晚期卵巢癌患者进行奥拉帕尼联合贝伐单抗维持治疗，并更新无进展生存期和最终总生存期。
期刊:International Journal of Gynecological Cancer
影响因子:4.7
doi:10.1136/ijgc-2023-004995
Lorusso, Domenica; Mouret-Reynier, Marie-Ange; Harter, Philipp; Cropet, Claire; Caballero, Cristina; Wolfrum-Ristau, Pia; Satoh, Toyomi; Vergote, Ignace; Parma, Gabriella; Nøttrup, Trine J; Lebreton, Coriolan; Fasching, Peter A; Pisano, Carmela; Manso, Luis; Bourgeois, Hugues; Runnebaum, Ingo; Zamagni, Claudio; Hardy-Bessard, Anne-Claire; Schnelzer, Andreas; Fabbro, Michel; Schmalfeldt, Barbara; Berton, Dominique; Belau, Antje; Lotz, Jean-Pierre; Gropp-Meier, Martina; Gladieff, Laurence; Lück, Hans-Joachim; Abadie-Lacourtoisie, Sophie; Pujade-Lauraine, Eric; Ray-Coquard, Isabelle
